Basel, Switzerland, 8 March 2018 – Lonza Consumer Health & Nutrition will showcase its pioneering ingredient solutions, formulation capabilities and dosage forms for the nutraceutical industry at Natural Products Expo West 2018 from 9-11 March 2108 in Anaheim, CA (USA). Combining science-backed ingredients and innovative encapsulation technologies, Lonza offers capabilities from product concept to commercialization with their unique combination of "function and form." Located at Booth #3305, Lonza Consumer Health & Nutrition will also feature a range of new and exciting product concepts targeting the sports nutrition and healthy-aging consumer markets.
Following the recent acquisition of Capsugel, Lonza Consumer Health & Nutrition will present its ingredient portfolio, formulation capabilities and cutting-edge delivery systems for the formulation of clean label supplements. Visitors to the three-day event will be able to explore the company’s broad portfolio of vegetarian capsules, which not only meet the rising demand for clean-label supplements but also solve numerous technical formulation challenges.
Product highlights include the industry-leading Vcaps® capsules, the first generation of HPMC capsules, as well as Vcaps® Plus capsules, which are non-GMO, gluten-free and preservative-free. Plantcaps® capsules are a vegetarian capsule made from pullulan, which is naturally fermented from tapioca. Plantcaps® capsules are a more natural alternative, offering Certified Vegan, Non-GMO, Vegetarian Society, Halal and Kosher certifications and can be used with liquid or powder filled ingredients. Plus, Plantcaps® offer an excellent oxygen barrier while masking pungent odors and protecting sensitive ingredients. In addition, in the US, these capsules may be used with organic ingredients so that the finished product can be labeled as made with organic.
Lonza Consumer Health & Nutrition will also further demonstrate its comprehensive solutions offering, with the launch of innovative science-backed product concepts for sports nutrition and healthy aging. One such concept targets joint-health flexibility, incorporating the company’s leading UC-II® ingredient, a patented clinically proven undenatured type II collagen, with further joint-health ingredients, such as krill oil and fish oil for enhanced benefits. Encapsulating UC-II® with curcumin provides another attractive proposition for supporting healthy joints.
Combining these ingredients in its revolutionary Capsugel patented capsule-in-capsule technology, DUOCAP®, offers multiple release profiles for usually incompatible products. By combining the company’s clinically proven ingredients and innovative dosage-forms, manufacturers can offer supplements that meet market needs and stand out in an increasingly competitive marketplace.
“As the demand for natural supplements continues to grow worldwide, consumers are looking for products that not only provide optimal results, but also meet the highest quality and ethical standards,” said June Lin, Head of Global Marketing for Consumer Health & Nutrition for Lonza. “As an integrated solutions provider, we offer a range of clinically proven ingredients and innovative dosage-form solutions, which are all manufactured to the highest quality standards and targeted at meeting the evolving needs of the consumer. Natural Products Expo West is a great opportunity for customers to speak with one of our industry experts on any complex formulation challenges or co-innovation opportunities they may have.”
More information is available at Booth #3305 and on www.lonza.com or www.capsugel.com
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.
Lonza Contact Information
| Dominik Werner, Head Corporate Communications Lonza Group Ltd |
| Tel +41 61 316 8798 |
Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.